Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors (RESET-PsO)

16 novembre 2026 mis à jour par: Xiangya Hospital of Central South University

Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Trial

This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.

Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.

Both groups receive recaticimab after the Week 16 assessments through Week 32, with safety follow-up at Week 36.

Aperçu de l'étude

Description détaillée

After screening of up to 4 weeks, participants are randomized 1:1 to recaticimab or matching placebo while continuing their established IL-17A inhibitor regimen.

Recaticimab 150 mg or matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After the Week 16 efficacy assessments, both groups receive recaticimab 150 mg at Weeks 16, 20, 24, 28, and 32. Safety follow-up is at Week 36, without study-drug administration. Post-Week 16 comparisons are exploratory.

A prespecified interim analysis may increase total enrollment from 100 to a maximum of 150 participants.

Type d'étude

Interventionnel

Inscription (Estimé)

100

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Yehong Kuang
  • Numéro de téléphone: +86 13574171102
  • E-mail: yh_927@126.com

Lieux d'étude

      • Shanghai, Chine
        • Shanghai Skin Disease Hospital
    • Hunan
      • Changde, Hunan, Chine
        • Changde First People's Hospital
      • Changsha, Hunan, Chine
        • The Second Xiangya Hospital of Central South University
      • Changsha, Hunan, Chine
        • Xiangya Hospital, Central South University
      • Changsha, Hunan, Chine
        • The Third Xiangya Hospital of Central South University
    • Liaoning
      • Dalian, Liaoning, Chine
        • Dalian Dermatology Hospital
      • Shenyang, Liaoning, Chine
        • Central Hospital Affiliated to Shenyang Medical College

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Participants must meet all of the following criteria:

  1. Understand the study requirements and procedures, voluntarily provide written informed consent, and be willing and able to comply with the protocol.

  2. Be male or female and aged 18 to 75 years, inclusive.

  3. Have a clinical diagnosis of plaque psoriasis that was moderate to severe before starting the current interleukin-17A (IL-17A) inhibitor.

  4. Meet the following prior-treatment and prior-response requirements for secondary treatment failure:

    Moderate-to-severe plaque psoriasis before starting the current IL-17A inhibitor must be supported by contemporaneous medical records. The investigator must verify the severity classification and its basis with reference to the Chinese Guidelines for the Diagnosis and Treatment of Psoriasis (2023 edition).

    The total duration of treatment with the current IL-17A inhibitor before enrollment must be at least 16 weeks. The actual cumulative dose received must be at least 80% of the cumulative dose calculated according to the product-label-recommended regimen over the same treatment period.

    A prior good clinical response during treatment with this drug must be supported by verifiable medical records and meet at least one of the following four conditions:

    1. Recorded Psoriasis Area and Severity Index (PASI) scores demonstrate a reduction of at least 90% from the PASI score before starting that IL-17A inhibitor, corresponding to a PASI90 response.
    2. Contemporaneous medical records document a static Physician's Global Assessment (sPGA) or Investigator's Global Assessment (IGA) score of 0 or 1, with these categories corresponding to clear or almost clear on the scale used.
    3. Contemporaneous physician records explicitly document clear or almost clear skin lesions.
    4. Contemporaneous medical records document that the percentage of body surface area affected by psoriasis (BSA) decreased to 1% or less during treatment with the same current IL-17A inhibitor.

    The requirement for documented moderate-to-severe disease before treatment applies to all four pathways. Available pretreatment PASI, BSA, sPGA/IGA, Dermatology Life Quality Index (DLQI), and clinical severity assessments must be recorded; all four scales are not required. The PASI90 pathway requires PASI values from both before and during treatment with that drug. Each other pathway requires the relevant on-treatment record and evidence of moderate-to-severe disease before treatment. The investigator must verify the drug, dates, overall skin involvement, and source of evidence. Patient recall alone or a history of biologic use alone is insufficient. Missing historical scores must not be reconstructed.

  5. After achieving at least one of the good-response criteria above, have subsequent worsening while continuing the same IL-17A inhibitor, with PASI ≥3 and sPGA ≥2 at both screening and the Week 0 baseline visit, and an investigator judgment that a change in treatment strategy is needed. The investigator must review the prior response, worsening, and treatment records to confirm their temporal sequence and determine that the current worsening is not primarily attributable to treatment interruption or substantial nonadherence.

  6. Have dyslipidemia with fasting low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L and <4.9 mmol/L, without atherosclerotic cardiovascular disease (ASCVD).

  7. Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. Male and female participants of reproductive potential must agree to use highly effective contraception throughout the study and for 30 days after the last dose of study drug. Participants must also comply with the contraception requirements for their background IL-17A inhibitor. Any longer contraception periods specified in the applicable prescribing information or investigator's brochure must also be observed.

  8. Be willing to complete the required protocol examinations and assessments. Participation in optional assessments is voluntary, and declining them does not affect eligibility for the main study.

Exclusion Criteria:

Participants meeting any of the following criteria are excluded:

  1. A diagnosis of non-plaque psoriasis at screening or baseline, including guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis.
  2. Severe hypersensitivity to an active ingredient or any excipient of the study drugs.
  3. Concomitant malignancy.
  4. Any previous or current PCSK9-targeted therapy, including PCSK9 monoclonal antibodies or PCSK9-targeting small interfering RNA (siRNA) drugs, such as inclisiran.
  5. Current treatment at screening with other lipid-lowering drugs, such as statins or ezetimibe. Clinically necessary lipid-lowering treatment must not be discontinued to meet study eligibility criteria.
  6. Treatment with a biologic targeting a pathway other than IL-17A, or a small-molecule targeted drug, within 4 weeks before screening.
  7. Clinically significant active disease, such as active tuberculosis or active hepatitis.
  8. Participation in another clinical trial with use of a trial-related drug within 3 months before screening.
  9. Pregnancy, breastfeeding, or planned pregnancy during the study; or unwillingness of a male or female participant to use contraception.
  10. Major surgery within 3 months before screening or planned major surgery during the study.
  11. Renal impairment with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² during screening.
  12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN), or total bilirubin >2 times ULN.
  13. New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction <30%.
  14. Previously or currently diagnosed ASCVD, including coronary heart disease, ischemic stroke, or atherosclerotic peripheral artery disease; or another type of stroke within 3 months before randomization.
  15. A need to promptly initiate, continue, or intensify lipid-lowering drug therapy, based on an assessment of overall ASCVD risk and lipid-lowering treatment needs according to the Chinese Guidelines for Lipid Management (2023), such that treatment should not be delayed during the 16-week controlled treatment period.
  16. Any other condition that, in the investigator's judgment, makes participation inappropriate.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Recaticimab Plus Background IL-17A Inhibitor

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Recaticimab 150 mg is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants receive recaticimab 150 mg subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency.

Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments.

Comparateur placebo: Placebo Plus Background IL-17A Inhibitor

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency. Matching placebo is administered subcutaneously at Weeks 0, 4, 8, and 12. After completion of the Week 16 PASI75 primary endpoint assessment and other prespecified efficacy assessments, participants switch to recaticimab 150 mg administered subcutaneously at Weeks 16, 20, 24, 28, and 32. A safety follow-up visit is conducted at Week 36; no recaticimab or placebo is administered at that visit.

Participants continue treatment with the same IL-17A inhibitor used before enrollment, at the same maintenance dose and dosing frequency.

Recaticimab 150 mg is administered subcutaneously every 4 weeks. Participants assigned to the experimental arm receive recaticimab at Weeks 0, 4, 8, 12, 16, 20, 24, 28, and 32. Participants assigned to the placebo comparator arm receive recaticimab at Weeks 16, 20, 24, 28, and 32, after completion of the Week 16 primary endpoint and other prespecified efficacy assessments.

Matching placebo is administered subcutaneously to participants assigned to the placebo comparator arm at Weeks 0, 4, 8, and 12 during the double-blind, placebo-controlled period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of participants achieving PASI75 at Week 16
Délai: Week 16

PASI75 is defined as a ≥75% reduction in the Psoriasis Area and Severity Index (PASI) score from the Week 0 randomization baseline.

Week 16

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Mean percentage improvement from baseline in sPGA × BSA at Week 16
Délai: Baseline (Week 0) and Week 16

sPGA × BSA is the sPGA score multiplied by affected BSA (%). Mean individual percentage improvement is calculated as 100 × (Week 0 value - Week 16 value) / Week 0 value.

Baseline (Week 0) and Week 16
Mean change from baseline in PASI score
Délai: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Mean change from the Week 0 PASI score. PASI ranges from 0 to 72; higher scores indicate more severe disease.

Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Mean percentage improvement from baseline in PASI score
Délai: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Mean of individual percentage improvements in PASI: 100 × (Week 0 score - post-baseline score) / Week 0 score. Higher values indicate greater improvement.

Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI50
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with at least a 50% reduction in PASI from the Week 0 randomization baseline.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI90
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with at least a 90% reduction in PASI from the Week 0 randomization baseline.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants achieving PASI100
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with a 100% reduction in PASI from the Week 0 randomization baseline.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Percentage of participants with sPGA 0 or 1
Délai: Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Percentage with a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear). The scale ranges from 0 to 4.

Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Change from baseline in skin itch Numeric Rating Scale score
Délai: Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32

Change from Week 0 in skin itch Numeric Rating Scale (NRS) score, ranging from 0 (no itch) to 10 (worst imaginable itch).

Baseline and Weeks 4, 8, 12, and 16; exploratory extension at Weeks 20, 24, 28, and 32
Change from baseline in Dermatology Life Quality Index score
Délai: Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36

Change from the last valid pre-dose Dermatology Life Quality Index (DLQI) score. Scores range from 0 to 30; higher scores indicate worse quality of life.

Baseline and Weeks 8 and 16; exploratory extension/follow-up at Weeks 32 and 36
Percentage change from baseline in low-density lipoprotein cholesterol
Délai: Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32

Percentage change in LDL-C: 100 × (post-baseline - baseline) / baseline. Baseline is the last valid pre-dose measurement.

Baseline and Weeks 8 and 16; exploratory extension at Weeks 24 and 32
Participants with treatment-emergent adverse events
Délai: From the first study dose through Week 36

Number and percentage of participants with adverse events occurring after the first study dose through the final safety follow-up visit.

From the first study dose through Week 36

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

10 novembre 2026

Achèvement primaire (Estimé)

30 avril 2028

Achèvement de l'étude (Estimé)

30 septembre 2028

Dates d'inscription aux études

Première soumission

16 novembre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner